Review highlights the role of p38 MAPK in rheumatoid arthritis treatment, suggesting new therapeutic pathways.
The importance of p38 MAPK inhibitors as new drug for rheumatoid arthritis is reflected by the large number of compounds that has been developed over the last years. In this review new insights such as non-stressful activation of p38 MAPK, and the role of p38 MAPK in regulation of NF-kappaB recruitment are also discussed.
No takes yet. Share an insight, caveat, or question.
Westra et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: